207 related articles for article (PubMed ID: 9326239)
21. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
22. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
[TBL] [Abstract][Full Text] [Related]
23. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M; Burke GA; Lowis SP; Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
[TBL] [Abstract][Full Text] [Related]
24. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
[TBL] [Abstract][Full Text] [Related]
25. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
Styczynski J; Koltan A; Wysocki M
Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.
Coustan-Smith E; Kitanaka A; Pui CH; McNinch L; Evans WE; Raimondi SC; Behm FG; Aricò M; Campana D
Blood; 1996 Feb; 87(3):1140-6. PubMed ID: 8562940
[TBL] [Abstract][Full Text] [Related]
27. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
[TBL] [Abstract][Full Text] [Related]
28. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype.
Ramakers-van Woerden NL; Beverloo HB; Veerman AJ; Camitta BM; Loonen AH; van Wering ER; Slater RM; Harbott J; den Boer ML; Ludwig WD; Haas OA; Janka-Schaub GE; Pieters R
Leukemia; 2004 Mar; 18(3):521-9. PubMed ID: 14712291
[TBL] [Abstract][Full Text] [Related]
29. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
Ramakers-van Woerden NL; Pieters R; Hoelzer D; Slater RM; den Boer ML; Loonen AH; Harbott J; Janka-Schaub GE; Ludwig WD; Ossenkoppele GJ; van Wering ER; Veerman AJ;
Med Pediatr Oncol; 2002 Jun; 38(6):379-86. PubMed ID: 11984797
[TBL] [Abstract][Full Text] [Related]
30. Individualized tumor response testing profile has a prognostic value in childhood acute leukemias: multicenter non-interventional long-term follow-up study.
Piatkowska M; Styczynski J; Kolodziej B; Kurylo-Rafinska B; Kubicka M; Pogorzala M; Czyzewski K; Debski R; Matysiak M; Malinowska I; Balwierz W; Juraszewska E; Wachowiak J; Konatkowska B; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak MJ; Badowska W; Szczepanski T; Tomaszewska R; Adamkiewicz-Drozynska E; Maciejka-Kapuscinska L; Sobol G; Mizia-Malarz A; Wysocki M
Leuk Lymphoma; 2013 Jun; 54(6):1256-62. PubMed ID: 23088710
[TBL] [Abstract][Full Text] [Related]
31. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
Holleman A; Cheok MH; den Boer ML; Yang W; Veerman AJ; Kazemier KM; Pei D; Cheng C; Pui CH; Relling MV; Janka-Schaub GE; Pieters R; Evans WE
N Engl J Med; 2004 Aug; 351(6):533-42. PubMed ID: 15295046
[TBL] [Abstract][Full Text] [Related]
32. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia.
Rivera GK; Hudson MM; Liu Q; Benaim E; Ribeiro RC; Crist WM; Pui CH
Blood; 1996 Aug; 88(3):831-7. PubMed ID: 8704238
[TBL] [Abstract][Full Text] [Related]
34. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
Ramakers-van Woerden NL; Pieters R; Loonen AH; Hubeek I; van Drunen E; Beverloo HB; Slater RM; Harbott J; Seyfarth J; van Wering ER; Hählen K; Schmiegelow K; Janka-Schaub GE; Veerman AJ
Blood; 2000 Aug; 96(3):1094-9. PubMed ID: 10910927
[TBL] [Abstract][Full Text] [Related]
35. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
36. Acute lymphoblastic leukemia in infants.
Gürgey A; Yetgin S; Cetin M; Gümrük F; Tuncer AM; Tunçbilek E; Hiçsönmez G
Turk J Pediatr; 2004; 46(2):115-9. PubMed ID: 15214738
[TBL] [Abstract][Full Text] [Related]
37. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia.
Frost BM; Nygren P; Gustafsson G; Forestier E; Jonsson OG; Kanerva J; Nygaard R; Schmiegelow K; Larsson R; Lönnerholm G;
Br J Haematol; 2003 Aug; 122(3):376-85. PubMed ID: 12877664
[TBL] [Abstract][Full Text] [Related]
38. Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador.
Bonilla M; Moreno N; Marina N; deReyes G; Shurtleff SA; Downing JR; Behm FG; Harrison PL; Ribeiro RC; Peña O; Crist WM; Antillon FG
J Pediatr Hematol Oncol; 2000; 22(6):495-501. PubMed ID: 11132215
[TBL] [Abstract][Full Text] [Related]
39. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.
Kaspers GJ; Kardos G; Pieters R; Van Zantwijk CH; Klumper E; Hählen K; de Waal FC; van Wering ER; Veerman AJ
Leukemia; 1994 Jul; 8(7):1224-9. PubMed ID: 8035616
[TBL] [Abstract][Full Text] [Related]
40. [Drug sensitivity of tumor cells in varieties of acute childhood leukemia].
Shman TV; Belevtsev MV; Buglova SE
Vopr Onkol; 2005; 51(5):558-62. PubMed ID: 16756010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
